Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatments for viral and other diseases by blocking genes

26.05.2008
The elusive goal of developing effective treatments for viral diseases such as AIDS and influenza has been brought closer by dramatic progress in the ability to interfere with viral genetic machinery. The stage was set for a coordinated European effort to accelerate research and stimulate development of new treatments against viral diseases at a recent research conference organised by the European Science Foundation (ESF).

It has been possible for many years to protect against some viral diseases such as polio in advance by vaccination, but there is still no effective treatment for patients once infection has occurred. Furthermore vaccination has not been possible so far against some diseases such as AIDS, and is only partially successful against some others, such as influenza.

However there is now the possibility of developing treatments potentially against all viral diseases through drugs based on the recently discovered phenomenon of RNA interference (RNAi), as was discussed at the ESF conference. The interference is performed by small RNA molecules known as siRNAs (small interfering RNAs).

RNA is produced when genes are expressed, normally as an intermediate step in the production of the end product, proteins. In some cases though expression stops with short RNA molecules, which in turn regulate the activity of other genes. Such molecules are called microRNAs, of which siRNAs can be considered a sub-category. It has already been shown that siRNAs occur naturally in plants as a defence mechanism against viral infection, but it is not known whether they occur in animals as Jens Kurreck pointed out, who organized the conference together with Ben Berkhout,. "An important question is whether RNAi is a natural cellular defense mechanism in mammals including humans," said Kurreck.

If it turns out that siRNAs do occur naturally in humans, researchers will attempt to stimulate or reinforce them to treat viral diseases more effectively than they normally do. If they do not occur naturally, then the line would be to create artificial siRNA molecules exploiting knowledge of how plants produce and apply them in their innate immune defences.

Although the basic mechanisms of RNA interference are now quite well understood, significant challenges remain in applying the technique in treatment of disease. A major issue lies in the ability of viruses to "escape" siRNA molecules by mutating so that they are no longer susceptible, according to Kurreck. These mutations prevent siRNA molecules from binding to relevant sites on the virus, so that it can reproduce without interference. One solution to prevent viruses escaping from RNAi in this way would be to combine several different treatments. "In analogy with the combination of several drugs in conventional virus therapy, various siRNAs against the virus can be combined to prevent viral escape," said Kurreck. The idea is that the virus might be able to evade one siRNA, but could not duck the combined effect of several.

Another challenge lies in ensuring that siRNAs are specific and inhibit the genetic machinery just of the target virus, without impairing vital cellular processes, with knock on effects for the immune system as a whole perhaps.

RNAi treatments are not just for the future - some are close to reality, particularly against respiratory diseases, since it is easier to deliver the drugs into the lung. "Two clinical trials to use RNAi against viruses are ongoing," said Kurreck. "There is a phase II trial with siRNAs against the Respiratory Syncitial Virus, and a phase I trial to treat patients infected with HIV." Phase I trials are usually conducted on small groups of people to assess safety, while in Phase II larger numbers of volunteers are recruited, typically around 300, to assess the effectiveness of the drug.

While the most immediate promise of RNAi is for treating viral diseases, it has equally exciting potential against other diseases such as macular degeneration, and some cancers. Here too real progress has been made. "Three clinical trials are ongoing to treat patients with age-related macular degeneration. Furthermore, one talk at the conferences was about the use of RNAi against cancer. A clinical trial for that was announced to begin at the end of 2008," said Kurreck.

Thomas Lau | alfa
Further information:
http://www.esf.org/index.php?id=2504

More articles from Health and Medicine:

nachricht New antibody analysis accelerates rational vaccine design
09.08.2018 | Scripps Research Institute

nachricht Distrust of power influences choice of medical procedures
01.08.2018 | Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

Im Focus: World record: Fastest 3-D tomographic images at BESSY II

The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.

Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...

Im Focus: A molecular switch may serve as new target point for cancer and diabetes therapies

If certain signaling cascades are misregulated, diseases like cancer, obesity and diabetes may occur. A mechanism recently discovered by scientists at the Leibniz- Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin and at the University of Geneva has a crucial influence on such signaling cascades and may be an important key for the future development of therapies against these diseases. The results of the study have just been published in the prestigious scientific journal 'Molecular Cell'.

Cell growth and cell differentiation as well as the release and efficacy of hormones such as insulin depend on the presence of lipids. Lipids are small...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Can radar replace stethoscopes?

14.08.2018 | Medical Engineering

The end-Cretaceous extinction unleashed modern shark diversity

14.08.2018 | Life Sciences

Light-controlled molecules: Scientists develop new recycling strategy

14.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>